Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788697 · ClinicalTrials.gov registry record · Phase 3
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
A Phase 3 study of Liver Neoplasms, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 3
- Development phase
- 349
- Enrollment target
- 1
- Study location
NCT00788697 is a Phase 3 study of Liver Neoplasms that has completed, run by Bracco Diagnostics. The registered enrollment target is 349 participants, below the 439-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00788697, a Phase 3 study of Liver Neoplasms, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 349 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate the superiority of SonoVue®-enhanced ultrasound versus unenhanced ultrasound for characterization of Focal Liver Lesions using final diagnosis based on histology or combined imaging/clinical data as truth standard.
Conditions Studied
Interventions
- DRUG SonoVue-enhanced ultrasound
- OTHER Unenhanced ultrasound
Study Locations (1)
New Jersey
- Bracco Diagnostics Inc - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788697
The ClinicalTrials.gov registry entry for NCT00788697 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (21% lower). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which SonoVue-enhanced ultrasound is the first listed.
NCT00788697 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00788697 about?
NCT00788697 is a clinical study titled "SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization". The purpose of this study is to demonstrate the superiority of SonoVue®-enhanced ultrasound versus unenhanced ultrasound for characterization of Focal Liver Lesions using final diagnosis based on histology or combined imaging/clinical data as truth standard.
What is the current status of trial NCT00788697?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 349 participants. The study started on 2009-09. Estimated completion is 2013-07.
What conditions does trial NCT00788697 study?
This clinical trial studies the following conditions: Liver Neoplasms.
What interventions are being tested in trial NCT00788697?
The interventions under investigation include: SonoVue-enhanced ultrasound (DRUG), Unenhanced ultrasound (OTHER).
Who is sponsoring clinical trial NCT00788697?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00788697 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
RECRUITING · Phase 2
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
RECRUITING · Phase 2
-
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RECRUITING
-
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
ACTIVE NOT RECRUITING · NA
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.